US2006165692A1PendingUtilityA1

Humanized anti-CD3 specific antibodies

61
Assignee: BTG INT LTDPriority: Mar 24, 1992Filed: Dec 15, 2005Published: Jul 27, 2006
Est. expiryMar 24, 2012(expired)· nominal 20-yr term from priority
Inventors:Sarah BoltMichael ClarkScott GormanEdward RoutledgeHerman Waldman
C07K 16/00A61P 37/06A61K 2039/505C07K 2317/41C07K 16/2809C07K 2317/56C07K 2317/73C07K 2317/565C07K 2317/24A61P 35/00C07K 2317/74
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Novel aglycosylated antibodies having a binding affinity for the CD3 antigen complex are of value for use in therapy, particularly in immunosuppression.

Claims

exact text as granted — not AI-modified
1 - 27 . (canceled)  
     
     
         28 . A method of treating a patient having cancer which comprises administering to said patient a therapeutically effective amount of a ligand having a binding affinity for the CD3 antigen complex.

Join the waitlist — get patent alerts

Track US2006165692A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.